Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC)

Historical Holders from Q2 2015 to Q3 2025

Symbol
BPMC
CUSIP
09627Y109
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
62.5M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
26K
Holdings value
$2.57M
% of all portfolios
0%
Grand Portfolio weight change
-0.013%
Number of holders
4
Number of sells
-333
Average Value change %
-0.03%
Average sells %
-0.032%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8% $412M 5.09M BlackRock, Inc. Mar 31, 2025
Pentwater Capital Management LP 6% $501M 3.9M Pentwater Capital Management LP Jun 30, 2025
WELLINGTON MANAGEMENT GROUP LLP 4.8% $248M 3.07M Wellington Management Group LLP Mar 31, 2025
FMR LLC 3.5% $182M 2.25M FMR LLC Dec 31, 2024
PRICE T ROWE ASSOCIATES INC /MD/ 2.3% $188M 1.47M T. Rowe Price Associates, Inc. Jun 30, 2025
Avoro Capital Advisors LLC 0.6% -90% $48.2M -$447M 375K -90.3% Avoro Capital Advisors LLC Jun 30, 2025

Institutional Holders of Blueprint Medicines Corp - Common Stock, par value $0.001 per share (BPMC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 26K $2.57M -$8.21B $128.44 4
2025 Q2 64.3M $8.24B -$126M $128.18 349
2025 Q1 68.5M $6.06B +$140M $88.51 347
2024 Q4 67.1M $5.85B +$180M $87.22 336
2024 Q3 64.7M $5.99B -$229M $92.50 318
2024 Q2 66.2M $7.13B +$112M $107.78 306
2024 Q1 65.2M $6.19B +$140M $94.86 282
2023 Q4 242K $22.3M -$579K $92.24 4
2023 Q3 63.8M $3.21B +$13.4M $50.22 213
2023 Q2 62.7M $3.96B +$29M $63.20 212
2023 Q1 63.3M $2.84B +$37.4M $44.99 210
2022 Q4 62.6M $2.74B -$85.3M $43.81 215
2022 Q3 61M $4.02B -$119M $65.89 216
2022 Q2 53.8M $2.72B -$14.2M $50.51 211
2022 Q1 59.2M $3.78B -$42.9M $63.88 224
2021 Q4 58.6M $6.27B -$36M $107.11 263
2021 Q3 59.5M $6.12B +$226M $102.81 278
2021 Q2 53.8M $4.74B -$33.9M $87.96 273
2021 Q1 53.9M $5.24B +$94.3M $97.23 252
2020 Q4 53.2M $5.96B +$30.6M $112.15 265
2020 Q3 52.8M $4.89B +$120M $92.70 229
2020 Q2 52.4M $4.09B +$187M $78.00 223
2020 Q1 54.4M $3.18B +$194M $58.48 199
2019 Q4 50.7M $4.06B -$62.5M $80.11 216
2019 Q3 51.3M $3.77B +$142M $73.47 207
2019 Q2 49.5M $4.67B +$407M $94.33 215
2019 Q1 48.5M $3.88B +$227M $80.05 198
2018 Q4 45.5M $2.45B -$76.8M $53.91 153
2018 Q3 44.8M $3.5B +$28.7M $78.06 184
2018 Q2 44.3M $2.81B +$189M $63.48 176
2018 Q1 41.2M $3.78B +$86.8M $91.70 172
2017 Q4 42.7M $3.22B +$300M $75.41 164
2017 Q3 36.3M $2.53B +$48.1M $69.67 134
2017 Q2 35.6M $1.8B +$85.5M $50.67 122
2017 Q1 34.7M $1.38B +$410M $39.99 133
2016 Q4 26M $729M +$172M $28.05 100
2016 Q3 19.1M $568M +$17.1M $29.70 85
2016 Q2 19.5M $395M +$32.9M $20.25 81
2016 Q1 17.9M $323M -$4.07M $18.05 71
2015 Q4 18M $474M +$22.3M $26.34 74
2015 Q3 23M $489M +$12.8M $21.34 67
2015 Q2 23.1M $610M +$586M $26.49 68